Key points are not available for this paper at this time.
WHAT IS ALREADY KNOWN ON THIS TOPIC The US Food and Drug Administration (FDA) Priority Review Voucher (PRV) is one of a set of push-and-pull mechanisms to incentivise investments into medical innovation for otherwise neglected, non-profitable diseases for pharmaceutical companies and investors, but its effectiveness has been questioned.
Olliaro et al. (Sun,) studied this question.